Who are imiquimod cream, 3.75%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zyclara®, Imiquimod cream + surgery, Glatiramer acetate (Copaxone), TIMOFÉROL®, Thymosin alpha1 & Pegylated Interferon-alpha2a, bee venom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imiquimod-cream-3-75.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

imiquimod cream, 3.75% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

imiquimod cream, 3.75% (imiquimod cream, 3.75%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Dermatology.

phase 3 Immunomodulator TLR7, TLR8 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

imiquimod cream, 3.75% (imiquimod cream, 3.75%) — Actavis Mid-Atlantic LLC. Imiquimod cream works by activating the immune system to fight off abnormal cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
imiquimod cream, 3.75% TARGET	imiquimod cream, 3.75%	Actavis Mid-Atlantic LLC	phase 3	Immunomodulator	TLR7, TLR8
Zyclara®	Zyclara®	Actavis Inc.	marketed	Toll-like receptor agonist	TLR7, TLR8
Imiquimod cream + surgery	Imiquimod cream + surgery	Nantes University Hospital	phase 3	Toll-like receptor agonist (topical immune response modifier)	TLR7, TLR8
Glatiramer acetate (Copaxone)	Glatiramer acetate (Copaxone)	Federal University of São Paulo	marketed	Immunomodulator; disease-modifying therapy (DMT)	T cell receptor (indirect); myelin basic protein mimic
TIMOFÉROL®	TIMOFÉROL®	Assistance Publique - Hôpitaux de Paris	marketed	Thymic extract / Immunomodulator
Thymosin alpha1 & Pegylated Interferon-alpha2a	Thymosin alpha1 & Pegylated Interferon-alpha2a	Seoul National University Hospital	marketed	Immunomodulator combination	T-cell maturation pathway; interferon-alpha receptor (IFNAR)
bee venom	bee venom	Assistance Publique - Hôpitaux de Paris	marketed	Natural product immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). imiquimod cream, 3.75% — Competitive Intelligence Brief. https://druglandscape.com/ci/imiquimod-cream-3-75. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab